Editor's Special Episode: Future Directions in MPN Treatment with Dr. Hobbs
The HemOnc Pulse
00:00
BET inhibitor INC‑B057643: Phase I tolerability and signals
Nicole asks about the INC‑B057643 trial and Dr. Hobbs reviews safety, cytopenias, and early efficacy signals including spleen responses.
Play episode from 02:56
Transcript
